These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38575192)

  • 1. Optimal [
    Gebhart G; Keyaerts M; Guiot T; Flamen P; Ruiz-Borrego M; Stradella A; Bermejo B; Escriva-de-Romani S; Calvo Martínez L; Ribelles N; Fernandez-Abad M; Albacar C; Colleoni M; Garrigos L; Atienza de Frutos M; Dalenc F; Prat A; Marmé F; Schmid P; Kerrou K; Braga S; Gener P; Sampayo-Cordero M; Cortés J; Pérez-García JM; Llombart-Cussac A
    J Nucl Med; 2024 May; 65(5):708-713. PubMed ID: 38575192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-year invasive disease-free survival with chemotherapy de-escalation using an
    Pérez-García JM; Cortés J; Ruiz-Borrego M; Colleoni M; Stradella A; Bermejo B; Dalenc F; Escrivá-de-Romaní S; Calvo Martínez L; Ribelles N; Marmé F; Cortés A; Albacar C; Gebhart G; Prat A; Kerrou K; Schmid P; Braga S; Di Cosimo S; Gion M; Antonarelli G; Popa C; Szostak E; Alcalá-López D; Gener P; Rodríguez-Morató J; Mina L; Sampayo-Cordero M; Llombart-Cussac A;
    Lancet; 2024 Apr; 403(10437):1649-1659. PubMed ID: 38582092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy de-escalation using an
    Pérez-García JM; Gebhart G; Ruiz Borrego M; Stradella A; Bermejo B; Schmid P; Marmé F; Escrivá-de-Romani S; Calvo L; Ribelles N; Martinez N; Albacar C; Prat A; Dalenc F; Kerrou K; Colleoni M; Afonso N; Di Cosimo S; Sampayo-Cordero M; Malfettone A; Cortés J; Llombart-Cussac A;
    Lancet Oncol; 2021 Jun; 22(6):858-871. PubMed ID: 34019819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.
    Groheux D; Giacchetti S; Hatt M; Marty M; Vercellino L; de Roquancourt A; Cuvier C; Coussy F; Espié M; Hindié E
    Br J Cancer; 2013 Sep; 109(5):1157-64. PubMed ID: 23942075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
    Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
    J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
    Connolly RM; Leal JP; Solnes L; Huang CY; Carpenter A; Gaffney K; Abramson V; Carey LA; Liu MC; Rimawi M; Specht J; Storniolo AM; Valero V; Vaklavas C; Krop IE; Winer EP; Camp M; Miller RS; Wolff AC; Cimino-Mathews A; Park BH; Wahl RL; Stearns V
    J Clin Oncol; 2021 Jul; 39(20):2247-2256. PubMed ID: 33999652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.
    Llombart-Cussac A; Pérez-García J; Brasó-Maristany F; Paré L; Villacampa G; Gion M; Schmid P; Colleoni M; Borrego MR; Galván P; Parker JS; Buckingham W; Perou CM; Villagrasa P; Guerrero JA; Sampayo-Cordero M; Mancino M; Prat A; Cortés J
    Clin Cancer Res; 2024 Sep; 30(18):4123-4130. PubMed ID: 38995291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and molecular predictors of [
    Llombart-Cussac A; Prat A; Pérez-García JM; Mateos J; Pascual T; Escrivà-de-Romani S; Stradella A; Ruiz-Borrego M; de Las Heras BB; Keyaerts M; Galvan P; Brasó-Maristany F; García-Mosquera JJ; Guiot T; Gion M; Sampayo-Cordero M; Di Cosimo S; Pérez-Escuredo J; de Frutos MA; Cortés J; Gebhart G
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2733-2743. PubMed ID: 38587643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial).
    Hennessy MA; Leal JP; Huang CY; Solnes LB; Denbow R; Abramson VG; Carey LA; Liu MC; Rimawi M; Specht J; Storniolo AM; Valero V; Vaklavas C; Winer EP; Krop IE; Wolff AC; Cimino-Mathews A; Wahl RL; Stearns V; Connolly RM
    J Nucl Med; 2023 Nov; 64(11):1690-1696. PubMed ID: 37652539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
    Humbert O; Cochet A; Riedinger JM; Berriolo-Riedinger A; Arnould L; Coudert B; Desmoulins I; Toubeau M; Dygai-Cochet I; Guiu S; Coutant C; Fumoleau P; Brunotte F
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1525-33. PubMed ID: 24647576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of
    Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
    Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
    Connolly RM; Leal JP; Solnes L; Huang CY; Carpenter A; Gaffney K; Abramson V; Carey LA; Liu MC; Rimawi M; Specht J; Storniolo AM; Valero V; Vaklavas C; Krop IE; Winer EP; Camp M; Miller RS; Wolff AC; Cimino-Mathews A; Park BH; Wahl RL; Stearns V
    J Clin Oncol; 2019 Mar; 37(9):714-722. PubMed ID: 30721110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of
    Lee IH; Lee SJ; Lee J; Jung JH; Park HY; Jeong SY; Lee SW; Chae YS
    BMC Cancer; 2020 Nov; 20(1):1106. PubMed ID: 33198673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
    J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtype-Guided
    Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
    Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
    Ueda S; Yoshizawa N; Shigekawa T; Takeuchi H; Ogura H; Osaki A; Saeki T; Ueda Y; Yamane T; Kuji I; Sakahara H
    J Nucl Med; 2016 Aug; 57(8):1189-95. PubMed ID: 26940765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
    Beitsch P; Whitworth P; Baron P; Rotkis MC; Mislowsky AM; Richards PD; Murray MK; Pellicane JV; Dul CL; Nash CH; Stork-Sloots L; de Snoo F; Untch S; Lee LA
    Ann Surg Oncol; 2017 Sep; 24(9):2539-2546. PubMed ID: 28447218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.